08:20 AM EDT, 06/19/2024 (MT Newswires) -- Avicanna ( AVCNF ) , a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, said Wednesday that the US Patent and Trademark Office has awarded the patent covering Avicanna's ( AVCNF ) self-emulsifying drug delivery system (SEDDS) oral cannabinoid composition and methods of treating neuropathic pain.

The company -- which saw its shares drop near 9% and nearer to 52 week lows yesterday -- said SEDDS oral delivery systems "offer a route for non-invasive and non-inhalation administration of cannabinoids".

Also, it added, the SEDDS technology demonstrated "shelf-life stability with more than 90% of the total cannabinoid(s) remaining after six months in accelerated conditions".

The patent number is US 11,998,632 B2.